CLINICAL PROFILE OF PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS IN NORTH INDIA

Main Article Content

Dr Aakash Aggarwal
Dr Vivek Ahuja
Dr Gaurav Singal
Dr Prateek Sharda
Dr Madhur Sharma

Keywords

UC (Ulcerative colitis), ASUC (Acute Severe Ulcerative Colitis), ruelove & Witts diagnostic criteria, thrombocytosis

Abstract

Background: Ulcerative colitis (UC) is an idiopathic inflammatory disease predominantly involving colo-rectum. About 1/5th of UC patients presents in the form of acute severe ulcerative colitis (ASUC) which carries a significant morbidity and mortality. It is diagnosed on the basis of Truelove and Witts criteria.


Materials and Methods: A total of 30 consecutive patients diagnosed to have ASUC according to Truelove & Witts criteria were enrolled in study. Their clinical and laboratory parameters were determined which included CBC, RFT, LFT, ESR, CRP – quantitative, albumin and stool for clostridium difficle. Study duration was 15 months, from November 2022 to January 2024.


Results: Mean age of the patients was 38.83 ± 13.35 years. 19/30 (63.3%) were males and 11/30 (36.6%) were females. Among the 30 total patients, 20 (66.6%) had preexisting ulcerative colitis and 10 (33.3%) had new onset disease with first presentation as ASUC. Most common cause of flare was poor compliance to medical treatment (n=17/20; 85%) followed by NSAID use (n=2/20; 10%) and supra added clostridium difficle infection (n=1/20; 5%). When Truelove & Witts criteria was applied, along with >6 bowel movements with visible blood most common additional feature was raised ESR (> 30 mm/hour), seen in 24 (80%) patients. It was followed by tachycardia (pulse rate >90/minute), seen in 20 (66.6%) patients.  Anaemia i.e. hemoglobin < 10.5 g% was present in 16 (53.3%) patients and fever (> 100.04°F) was present in 8 (26.6%) patients.


Most common clinical features were pain abdomen (n=25; 83.3%), followed by stool urgency (n=18; 60%) and tenesmus (n=7; 23.3%). Thrombocytosis was seen in (n=4; 13.3%) patients and hypoalbuminemia was seen in (n=11; 36.6%) patients.

Abstract 74 | pdf Downloads 37

References

1. TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041.
2. Macken L, Blaker PA. Management of acute severe ulcerative colitis (NICE CG 166). Clinical Medicine. 2015 Oct 10;15(5):473.
3. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.
4. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H, Alipour V. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet gastroenterology & hepatology. 2020 Jan 1;5(1):17-30.
5. Tandon BN, Mathur AK, Mohapatra LN et al. A study of the prevalence and clinical pattern of non-specific ulcerative colitis in northern India. Gut 1965; 6 (5): 448- 53.
6. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003 Nov 1;52(11):1587-90.
7. Sood A, Midha V, Sood N, Puri S, Kaushal V. Profile of ulcerative colitis in a north Indian hospital. J Indian Acad Clin Med. 2000;5:125-9.
8. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus Jr EV. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clinical Gastroenterology and Hepatology. 2017 Jun 1;15(6):857-63.
9. Yang BR, Choi NK, Kim MS, Chun J, Joo SH, Kim H, Lee J. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients. PLoS One. 2018 Jul 10;13(7):e0200363.
10. Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Disease-a-month. 2019 Dec 1;65(12):100851.
11. Soni A. Clinical Profile of Ulcerative Colitis Patients in a Tertiary Care Center: An Experience from Rural India. Indian Journal of Surgery. 2021 Aug;83(4):915-9.
12. Langholz E, Munkholm PI, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994 Jul 1;107(1):3-11.
13. Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF, George B, Mortensen NJ, Travis SP. The pattern and outcome of acute severe colitis. Journal of Crohn's and Colitis. 2010 Oct 1;4(4):431-7.
14. Maroo MK, Nag NK, Sortur SV, Patil RS. Ulcerative colitis in Southern Maharashtra. Journal of the Indian Medical Association. 1974 Dec 1;63(11):350-4.
15. Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Therapeutic advances in chronic disease. 2018 Feb;9(2):65-72.
16. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Digestive diseases and sciences. 2006 Jan;51:168-72.
17. Giles C. The platelet count and mean platelet volume. British journal of haematology. 1981 May;48(1):31-7.
18. Voudoukis E, Karmiris K, Oustamanolakis P, Theodoropoulou A, Sfiridaki A, Paspatis GA, Koutroubakis IE. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. European journal of gastroenterology & hepatology. 2013 Oct 1;25(10):1212-6.
19. Zhou Y, Zhu F, Jing D, Wang Q, Zhou G. Ulcerative colitis and thrombocytosis: Case report and literature review. Medicine. 2023 May 19;102(20):e33784.
20. Khan N, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. World Journal of Gastroenterology. 2017 Dec 12;23(45):8008.